The company initiates the first-in-human clinical study of JWATM214 for advanced HCC. The study focuses to evaluate the safety & tolerability, determine the RP2D & assess the PK profile & preliminary efficacy of JWATM214 for GPC-3-expressing advanced HCC
JWATM214 is an autologous T-cell immunotherapy candidate drug targeting GPC-3 that has been developed using Eureka’s ARTEMIS technology & Lyell’s T-cell anti-exhaustion technology
In 2020, JW Therapeutics collaborated with Eureka & Lyell and in-licensed the rights to Eureka’s ARTEMIS technology & Lyell’s T cell anti-exhaustion technology to develop, manufacture & commercialize products in China (incl. mainland China, Hong Kong, Macao & Taiwan) along with ASEAN member states
Ref: PRNewswire | Image: JW Therapeutics
Related News:- JW Therapeutics Receives the NMPA’s Approval for Carteyva (relmacabtagene autoleucel) sNDA to Treat Relapsed or Refractory Follicular Lymphoma
